Nanexa announced today that the first pharmacokinetic (PK) samples from the final dose group, 30 mg, in the ongoing Phase I study for NEX-22 have been analyzed. The results show that the PK profile is similar to that of previous dose groups and that plasma exposure continues to increase with higher doses.
"The NEX-22 study is an important part of our research and development, and these preliminary results are very encouraging", says David Westberg, CEO Nanexa. "The results indicate that the treatment has a predictable and dose-dependent pharmacokinetic profile, which provides a good foundation for the upcoming Phase Ib study in the NEX-22 project. It is also a positive sign for the development of other long-acting injectable drugs with our PharmaShell technology."
We look forward to completing this study after the final clinical visits taking place this week and to sharing further results as they become available.
For additional information, please contact:
David Westberg - CEO, Nanexa AB (publ)
Phone: +46 70 942 83 03
Email: david.westberg@nanexa.se
www.nanexa.com
The company's Certified Adviser is Carnegie Investment Bank AB (publ).
About Nanexa AB (publ)
Nanexa is a pharmaceutical company developing injectable drug products based on the proprietary and innovative drug delivery system PharmaShell® - the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. Nanexa develops its own products and also has collaboration agreements with several pharma companies, among others Novo Nordisk and AstraZeneca.
Nanexa's share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).
